Cantitate/Preț
Produs

Infectious Complications in Biologic and Targeted Therapies

Editat de Carlos Cervera, Jose Maria Aguado
en Limba Engleză Paperback – 19 noi 2023
This book aims to approach the epidemiology, diagnosis and management of infectious complications related to the use of biologic and targeted therapies. The first part is a general overview on the epidemiology and prevention of infections with the use of these agents. Timelines, pre-treatment evaluation, use of vaccines and travel counseling. In the second part, we will analyze the specific risk of infections associated with the use of the most important agents. The third part approach the problem on a syndromic point of view. For example, how to evaluate pulmonary infiltrates in a patient receiving biologic agents. This part III includes the most difficult and conflicting syndromes that clinicians may face when evaluating these patients.

This book is intended not only for infectious diseases specialists, but also for different medical specialties prescribing biologic and targeted therapies.

Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 74364 lei  38-44 zile
  Springer International Publishing – 19 noi 2023 74364 lei  38-44 zile
Hardback (1) 93894 lei  38-44 zile
  Springer International Publishing – 19 noi 2022 93894 lei  38-44 zile

Preț: 74364 lei

Preț vechi: 78279 lei
-5% Nou

Puncte Express: 1115

Preț estimativ în valută:
14242 14673$ 11930£

Carte tipărită la comandă

Livrare economică 19-25 februarie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783031113659
ISBN-10: 3031113659
Pagini: 473
Ilustrații: X, 473 p. 26 illus., 19 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 0.87 kg
Ediția:1st ed. 2022
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland

Cuprins

Overview on the risk of infection associated with biologic and targeted therapies.- Timeline of infections associated with biologic and targeted therapies.- Infectious disease evaluation of candidates to new therapies.- Vaccines and biologic and targeted therapies.- Travel and risk of infections.- Anti-necrosis tumoral factor-alpha agents.- CD19-targeted agents.- CD20-targeted agents.- CD22-targeted agents.- CD30-targeted agents.- CD33 and CD38-targeted agents.- CD40 and CD319-targeted agents.- CD52-targeted agents.- CCR4-targeted agents.- Cell-surface receptors I: VEFG targeted agents.- Cell-surface receptors II: Epidermal growth factor receptor-targeted agents.- Interleukin-1 targeted agents.- Interleukin-5 and interleukin-6 targeted agents.- Interleukin-12/23 p40 targeted agents.- Sphingosine-1 phosphate receptor modulators.- Immune checkpoint inhibitors.- α4-integrin-targeted agents.- Tyrosin-kinase inhibitors.- Bcl-2, JAK and mTOR inhibitors.- Infections associated with the use ofCarT cells.- Pulmonary infiltrates.- Tuberculosis.- Cytomegalovirus and other herpesviruses.- Invasive fungal infections.- Progressive multifocal leukoencephalopathy.- Hepatitis virus.

Notă biografică

Carlos Cervera, MD, PhD
Division of Infectious Diseases, Department of Medicine. 
University of Alberta.
1-124F Clinical Sciences Building. 11350 83 Ave. 
Edmonton T6G 2G3
Alberta, Canada
Primary email address: cerveraa@ualberta.ca

Jose Maria Aguado, MD, PhD
Unit of Infectious Diseases, 
Research Institute Hospital "12 de Octubre" (i + 12),
University Hospital “12 de Octubre”, 
Complutense University of Madrid
Madrid, Spain
Primary email address: jaguadog1@gmail.com


Textul de pe ultima copertă

This book aims to approach the epidemiology, diagnosis and management of infectious complications related to the use of biologic and targeted therapies. The first part is a general overview on the epidemiology and prevention of infections with the use of these agents. Timelines, pre-treatment evaluation, use of vaccines and travel counseling. In the second part, we will analyze the specific risk of infections associated with the use of the most important agents. The third part approach the problem on a syndromic point of view. For example, how to evaluate pulmonary infiltrates in a patient receiving biologic agents. This part III includes the most difficult and conflicting syndromes that clinicians may face when evaluating these patients.

This book is intended not only for infectious diseases specialists, but also for different medical specialties prescribing biologic and targeted therapies.


Caracteristici

Provides a general overview on the epidemiology and prevention of infections Analyzes the specific risk of infections associated with the use of the most important agents Includes the most difficult and conflicting syndromes